S-1: Autonomix Medical Seeks $11.5 Million in Unit Offering to Advance Nervous System Disorder Treatments

Sentiment:

S-1 Filing 1 November 2024 9:03 AM

Autonomix Medical launches a unit offering to raise capital for clinical trials and development of its innovative nervous system disorder treatment platform.

Capital raiseAutonomix Medical is conducting a firm commitment public offering of 698,812 common stock units, each consisting of one share of common stock and one Series A warrant.The assumed public offering price is $14.31 per common stock unit, based on the last reported sale price on October 31, 2024.The company is also offering pre-funded warrant units (PFW Units) to purchasers who would otherwise exceed beneficial ownership limits.Each PFW Unit consists of one pre-funded warrant and one Series A warrant, with the pre-funded warrant exercisable at $0.001 per share.The company estimates net proceeds of approximately $9.0 million from the offering, to be used primarily for clinical trials and research and development.

Better than expectedPreliminary results from a proof-of-concept human clinical trial show positive outcomes for patients treated with femoral access for pancreatic cancer pain relief.

Summary

Autonomix Medical, a development stage medical device company, is offering common stock units and pre-funded warrant units to raise approximately $11.5 million.
Each common stock unit includes one share of common stock and one Series A warrant, while each pre-funded warrant unit includes one pre-funded warrant and one Series A warrant.
The offering aims to fund clinical trials, research and development, intellectual property development, and working capital.
Preliminary second quarter results show cash and cash equivalents of approximately $5.2 million as of September 30, 2024, and cash used in operations of $1.6 million for the quarter.
The company's technology platform focuses on sensing and treating nervous system disorders, initially targeting pancreatic cancer pain.
Autonomix has granted underwriters an option to purchase additional shares and/or warrants to cover over-allotments.
The company completed a 1-for-20 reverse stock split on October 24, 2024, to regain compliance with Nasdaq listing rules.
Preliminary results from a proof-of-concept human clinical trial show positive outcomes for patients treated with femoral access for pancreatic cancer pain relief.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there are positive aspects such as promising clinical trial results and innovative technology, the company faces significant financial challenges and risks, including going concern uncertainty and regulatory hurdles.

Positives

The offering will provide capital to advance clinical trials and development of the company's technology.
Preliminary clinical trial results show promising pain reduction and opioid elimination for pancreatic cancer patients.
The company's technology has significantly higher sensitivity compared to existing devices, potentially enabling more targeted treatments.
The company has secured a license agreement with RF Innovations for ablation technology.
The company has a broad patent portfolio covering its technology.
The company has a clear commercialization plan with a focus on pancreatic cancer pain management as a proof of concept.

Negatives

The company has an accumulated deficit of $41.7 million and negative cash flows from operating activities.
The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern.
The company is a development stage company with no approved products and a limited history of revenue generation.
The company relies on a single manufacturer for its lead product candidate.
The company received a deficiency letter from Nasdaq for failing to maintain a minimum bid price of $1.00 per share.
The company has determined that its internal controls were deemed to be inadequate, which could cause our financial reporting to be unreliable and lead to misinformation being disseminated to the public.

Risks

The company may not be able to raise additional funds on acceptable terms or at all.
The FDA may not grant clearance or approval for the company's products.
Clinical trials may be delayed or produce unfavorable results.
The company may face challenges in scaling up manufacturing and assembling its devices.
The company's products may be subject to recalls or adverse event reporting requirements.
The company may face intellectual property infringement claims.
The company may be at an increased risk of securities class action litigation.
The company may fail to meet the continued listing requirements of the Nasdaq which could result in de-listing of its common stock.

Future Outlook

The company expects to incur increased research and development costs in the future as it continues its clinical trial and product development efforts. The company estimates that it will require additional financing of approximately $40 million to fund its operations through initial commercial launch.

Management Comments

We believe, if we can recreate these results in clinical trials, this will enable a method of transvascular targeting, treating, and confirming treatment of diseases involving the nervous system throughout the body that is not currently available and may be capable of filling a wide range of unmet medical needs.
We believe one of the most demanding aspects of our commercialization plan will be scaling up from our existing sensing prototype to a robust commercial version.

Industry Context

The company operates in the electrophysiology market, which is expected to reach $11.6 billion by 2027. The company's technology aims to expand electrophysiology beyond cardiology to address a wider range of nervous system disorders.

Comparison to Industry Standards

The company's sensing technology boasts 3,000 times greater sensitivity than the nearest device on the market, the BSC Orion.
The Autonomix device has signal detection levels of <1uV and electrode dimensions of roughly 0.02mm by 0.03mm, compared to the BSC Orion's 10uV and 0.4mm by 0.5mm, respectively.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Chief Executive Officer	Lori Bisson	Brad Hauser	June 17, 2024	New appointment
Executive Vice Chair and Strategic Adviser to the Chief Executive Officer	NA	Lori Bisson	June 17, 2024	New appointment

Related Party Transactions

The company utilizes a consulting firm that is owned by Matthew Lourie, our former Chief Financial Officer, to provide accounting and financial reporting services and to pay certain expenses on behalf of the Company.
As part of the March 2022 sale of our common stock for cash, a member of the Board of Directors purchased 2,500 shares of common stock for $100,000 of cash proceeds.
As part of the March 2023 sale of common stock for cash, three members of the Board of Directors purchased, in the aggregate, 8,125 shares of common stock for $325,000 of cash proceeds.
In December 2021, we granted a company affiliated with certain early investors in the Company a exclusive worldwide license to our technology for use in the diagnosis and treatment of cardiovascular conditions and/or hypertension through renal denervation-based methods.
One of our directors, David Robins, holds a 19.5% interest in the company receiving the warrant.

Stakeholder Impact

Shareholders will experience immediate and substantial dilution in net tangible book value.
The company's ability to continue as a going concern is dependent upon successfully raising additional equity or debt financing to fund its operations.
The company's success is dependent on its ability to attract and retain qualified scientific, technical, and managerial personnel.

Next Steps

The company intends to use the proceeds from this offering primarily to fund its clinical trial, for other research and development, for development of intellectual property, and for working capital.
The company plans to present the relevant data from its Proof of Concept trial to the FDA in a pre-submission meeting to request Breakthrough Status in an effort to minimize the clinical requirements for clearance in the United States.
The company plans to bring sensing and treatment together in a pivotal clinical trial to enable the regulatory clearance and commercial launch of our technology.

Key Dates

Date	Description
June 10, 2014	Autonomix Medical, Inc. organized as a Delaware corporation.
December 21, 2021	Company granted a company affiliated with certain early investors in the Company a exclusive worldwide license to our technology for use in the diagnosis and treatment of cardiovascular conditions and/or hypertension through renal denervation-based methods.
July 7, 2023	Company entered into an Exclusive License Termination Agreement (the Termination Agreement) with the Licensee in exchange for the issuance, upon the closing of our IPO within one year of the agreements execution, of a warrant to purchase shares of the Company for a variable number of shares based on a value of $8.0 million.
September 9, 2023	Board of Directors authorized an offering up to $2.0 million in unsecured, non-interest bearing convertible promissory notes (the Notes) and accompanying warrants (the Bridge Financing Warrants) (collectively, the Bridge Offering) that will mature on December 31, 2025.
October 24, 2024	Company completed a 1-for-20 reverse stock split.
January 26, 2024	Company consummated its IPO.
June 17, 2024	Company entered into an employment agreement with Brad Hauser pursuant to which Mr. Hauser agreed to serve as our chief executive officer and president for an initial three-year period, which may be extended on a year-to-year basis.
June 17, 2024	Company entered into an employment agreement with Lori Bisson pursuant to which Ms. Bisson agreed to serve as our Executive Vice Chair and Strategic Adviser to the Chief Executive Officer (Vice Chair) for a two-year period.
July 10, 2024	Company entered into a license agreement (the Agreement) with RF Innovations, Inc. (RFI), a privately held medical technology company, to license products utilizing RFIs intellectual property related to its Apex 6 Radiofrequency Generator (the Licensed Products).
September 16, 2024	Company received a deficiency letter from the Listing Qualifications Department (the Staff) of the Nasdaq Stock Market (Nasdaq) notifying us that for the last 30 consecutive business days the closing bid price for our common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the Bid Price Rule).
October 17, 2024	Company held its annual meeting, our stockholders approved an amendment to our certificate of incorporation (the Amendment) to effect a reverse stock split of the outstanding shares of our common stock, at a split ratio of between 1-for-2 and 1-for-50 as determined by our board of directors in their sole discretion, prior to the one-year anniversary of the annual meeting.
October 28, 2024	Company highlighted positive preliminary results from the first five lead-in patients in our ongoing proof-of-concept human clinical trial (the Trial) evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain.
October 31, 2024	Company highlighted positive preliminary results from the first 15 patients, including five (5) lead-in patients.

Keywords

medical devices, nervous system, clinical trials, pancreatic cancer, ablation, sensing technology, warrants, stock offering, AMIX, Autonomix

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.